NASDAQ:CARA - Cara Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $19.40 +0.36 (+1.89 %) (As of 04/26/2019 01:47 AM ET)Previous Close$19.04Today's Range$18.64 - $19.5452-Week Range$11.50 - $24.30Volume489,300 shsAverage Volume660,506 shsMarket Capitalization$767.23 millionP/E RatioN/ADividend YieldN/ABeta2.7 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease (CKD) associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from chronic kidney disease-associated pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that is in Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; and in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut. Receive CARA News and Ratings via Email Sign-up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CARA Previous Symbol CUSIPN/A CIK1346830 Webwww.caratherapeutics.com Phone203-406-3700Debt Debt-to-Equity RatioN/A Current Ratio4.16 Quick Ratio4.16Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$13.47 million Price / Sales56.96 Cash FlowN/A Price / Cash FlowN/A Book Value$3.40 per share Price / Book5.71Profitability EPS (Most Recent Fiscal Year)($2.06) Net Income$-74,010,000.00 Net MarginsN/A Return on Equity-69.12% Return on Assets-47.44%Miscellaneous Employees55 Outstanding Shares39,548,000Market Cap$767.23 million Next Earnings Date5/8/2019 (Estimated) OptionableOptionable Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions What is Cara Therapeutics' stock symbol? Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA." How were Cara Therapeutics' earnings last quarter? Cara Therapeutics Inc (NASDAQ:CARA) released its quarterly earnings data on Tuesday, March, 12th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.07. The biopharmaceutical company had revenue of $5.53 million for the quarter, compared to analyst estimates of $3.35 million. View Cara Therapeutics' Earnings History. When is Cara Therapeutics' next earnings date? Cara Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Cara Therapeutics. What price target have analysts set for CARA? 10 analysts have issued 1-year target prices for Cara Therapeutics' shares. Their forecasts range from $13.36 to $30.00. On average, they expect Cara Therapeutics' share price to reach $24.7360 in the next twelve months. This suggests a possible upside of 27.5% from the stock's current price. View Analyst Price Targets for Cara Therapeutics. What is the consensus analysts' recommendation for Cara Therapeutics? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cara Therapeutics. What are Wall Street analysts saying about Cara Therapeutics stock? Here are some recent quotes from research analysts about Cara Therapeutics stock: 1. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (3/15/2019) 2. Cantor Fitzgerald analysts commented, "Compelling P2 safety and clinical activity data have been used to guide the design and risk-reduce pivotal P3 studies of IV KORSUVA in CKD-aP hemodialysis pts, from which we expect data in 2019. Our conviction for this program is bolstered by the significant partnership signed with a worldwide provider of hemodialysis services, which we believe validates the clinical and commercial potential. In addition, clinical success in CKD-aP could translate to other indications associated with pruritus, such as chronic liver disease, which should expand KORSUVA’s market opportunity." (10/4/2018) Has Cara Therapeutics been receiving favorable news coverage? Media headlines about CARA stock have been trending somewhat positive recently, according to InfoTrie. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cara Therapeutics earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the next several days. Who are some of Cara Therapeutics' key competitors? Some companies that are related to Cara Therapeutics include Amicus Therapeutics (FOLD), Biohaven Pharmaceutical (BHVN), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), Portola Pharmaceuticals (PTLA), Reata Pharmaceuticals (RETA), Insmed (INSM), Mirati Therapeutics (MRTX), Arena Pharmaceuticals (ARNA), The Medicines (MDCO), PTC Therapeutics (PTCT), Uniqure (QURE) and AnaptysBio (ANAB). What other stocks do shareholders of Cara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Canopy Growth (CGC), Puma Biotechnology (PBYI), Zynerba Pharmaceuticals (ZYNE), 22nd Century Group (XXII), Insys Therapeutics (INSY), Novavax (NVAX), Lions Gate Entertainment (LGF.A), GW Pharmaceuticals PLC- (GWPH), BioMarin Pharmaceutical (BMRN) and Incyte (INCY). Who are Cara Therapeutics' key executives? Cara Therapeutics' management team includes the folowing people: Dr. Derek T. Chalmers, Co-Founder, Pres, CEO & Director (Age 55)Dr. Frédérique Menzaghi, Chief Scientific Officer and Sr. VP of R&D (Age 53)Dr. Joana Goncalves, Chief Medical Officer (Age 45)Dr. Joseph Stauffer, Consultant (Age 53)Dr. Michael E. Lewis, Co-Founder & Chief Scientific Advisor (Age 67) Who are Cara Therapeutics' major shareholders? Cara Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include First Manhattan Co. (2.48%), Mesirow Financial Investment Management Inc. (0.08%) and BNP Paribas Arbitrage SA (0.02%). Company insiders that own Cara Therapeutics stock include Dean Slagel, Derek T Chalmers, Frederique PhD Menzaghi, Joseph William Stauffer, Mani Mohindru and Scott Terrillion. View Institutional Ownership Trends for Cara Therapeutics. Which institutional investors are buying Cara Therapeutics stock? CARA stock was acquired by a variety of institutional investors in the last quarter, including First Manhattan Co., Mesirow Financial Investment Management Inc. and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Cara Therapeutics. How do I buy shares of Cara Therapeutics? Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cara Therapeutics' stock price today? One share of CARA stock can currently be purchased for approximately $19.40. How big of a company is Cara Therapeutics? Cara Therapeutics has a market capitalization of $767.23 million and generates $13.47 million in revenue each year. The biopharmaceutical company earns $-74,010,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Cara Therapeutics employs 55 workers across the globe. What is Cara Therapeutics' official website? The official website for Cara Therapeutics is http://www.caratherapeutics.com. How can I contact Cara Therapeutics? Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700. MarketBeat Community Rating for Cara Therapeutics (NASDAQ CARA)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 532 (Vote Outperform)Underperform Votes: 283 (Vote Underperform)Total Votes: 815MarketBeat's community ratings are surveys of what our community members think about Cara Therapeutics and other stocks. Vote "Outperform" if you believe CARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CARA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/26/2019 by MarketBeat.com StaffFeatured Article: What is a support level?